MedTrace Logo

Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage

NCT06326658 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 848

Last updated 2024-03-22

No results posted yet for this study

Summary

To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in the stabilized phase.

Conditions

Interventions

OTHER

Bufei Yishen Prescription Granule

The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.

Sponsors & Collaborators

  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

    collaborator OTHER

  • The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

    collaborator OTHER

  • Henan University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-05-01
Completion
2026-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326658 on ClinicalTrials.gov